TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.79 Consensus Target Price from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has received a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $11.79.

Several brokerages have commented on TLSI. Roth Mkm reissued a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Canaccord Genuity Group reduced their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target on the stock. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th.

TriSalus Life Sciences Price Performance

TLSI opened at $5.33 on Monday. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $10.42. The firm’s fifty day moving average price is $4.64 and its two-hundred day moving average price is $4.74. The company has a market capitalization of $162.53 million, a price-to-earnings ratio of -2.14 and a beta of 0.51.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, insider Sean Murphy purchased 15,000 shares of TriSalus Life Sciences stock in a transaction on Monday, January 27th. The stock was bought at an average cost of $5.31 per share, with a total value of $79,650.00. Following the transaction, the insider now owns 182,732 shares of the company’s stock, valued at $970,306.92. This represents a 8.94 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Mary T. Szela bought 5,030 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were acquired at an average price of $5.03 per share, with a total value of $25,300.90. Following the completion of the transaction, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at $2,209,422.47. This trade represents a 1.16 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 118,868 shares of company stock valued at $541,943. 32.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in TriSalus Life Sciences in the third quarter worth approximately $92,000. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the last quarter. Vestcor Inc bought a new stake in TriSalus Life Sciences in the third quarter worth approximately $108,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth $184,000. Finally, Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at $66,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.